Theodor Wuppermann

Theodor Wuppermann is a Partner on the Buyout team at Mérieux Equity Partners in Paris. MxEP says he joined the firm in June 2023 with 15 years of investment experience and a specific focus on healthcare transactions in Europe.

Before Mérieux Equity Partners, Wuppermann worked at Keensight Capital, where a Keensight-linked biography described him as a Director focused on European private-equity investing and healthcare. Keensight’s own site also references his 2019 joining as Associate Director. Earlier in his career, he worked at ArchiMed, a healthcare-focused European private equity firm, and began at capiton AG, a German mid-cap investment fund.

His education includes a Master’s degree from Rotterdam School of Management, Erasmus University, and international business studies at Maastricht University. L’Agefi reported his July 2024 promotion to Partner within Mérieux Equity Partners’ Buyout team.

• MxEP’s Buyout strategy targets “profitable and fast-growing European companies” with €20m to €80m equity tickets, with additional capacity through co-investment.
• The firm invests in either majority or minority stakes and can pursue buyouts or growth financing, with or without leverage at entry.
• Sector scope is healthcare only, across pharma, pharma services, patient services, MedTech, life science tools and diagnostics, and preventive medicine.
• The Buyout team emphasizes active ownership, supporting organic growth and M&A strategies alongside management teams.
• Wuppermann’s recent deal comments emphasize management quality, differentiated technical expertise, strong services reputation, international expansion potential, and build-up opportunities.